Literature DB >> 21145879

Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun N-terminal kinase.

Andrea V Leisewitz1, Eric I Zimmerman, Min Huang, Shannon Z Jones, Jing Yang, Lee M Graves.   

Abstract

Equilibrative nucleoside transporters (ENTs) are facilitative transporters broadly selective for pyrimidine and purine nucleosides and are essential for the modulation of nucleoside concentration and nucleoside analog availability. Resistance to nucleoside-derived drugs strongly correlates with a deficiency of ENT1 expression in several tumor cells. Thus, it is crucial to understand the mechanisms by which this transporter is modulated. Using a mouse myeloid leukemic cell line as a model, we investigated whether stress-activated kinases regulate ENT1 expression and function. JNK activation, but not p38 MAPK results in rapid loss of mENT1 function, mRNA expression and promoter activity. c-Jun but not the mutant c-Jun Ser63/73Ala, decreased mENT1 promoter activity. Moreover cJun bound to an AP-1 site identified at -1196 of the promoter, suggesting a specific role for this transcription factor in mENT1 regulation. We propose that activation of JNK-cJun pathway negatively regulates mENT1 and suggest that this mechanism might contribute to the development of nucleoside analog-derived drug resistance. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21145879      PMCID: PMC3018549          DOI: 10.1016/j.bbrc.2010.11.125

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  35 in total

Review 1.  Nitric oxide as a bioregulator of apoptosis.

Authors:  H T Chung; H O Pae; B M Choi; T R Billiar; Y M Kim
Journal:  Biochem Biophys Res Commun       Date:  2001-04-20       Impact factor: 3.575

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 3.  Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor.

Authors:  Catherine Dunn; Carolyn Wiltshire; Ann MacLaren; David A F Gillespie
Journal:  Cell Signal       Date:  2002-07       Impact factor: 4.315

4.  MEK inhibition enhances paclitaxel-induced tumor apoptosis.

Authors:  J P MacKeigan; T S Collins; J P Ting
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

Review 5.  The equilibrative nucleoside transporter family, SLC29.

Authors:  Stephen A Baldwin; Paul R Beal; Sylvia Y M Yao; Anne E King; Carol E Cass; James D Young
Journal:  Pflugers Arch       Date:  2003-06-28       Impact factor: 3.657

6.  Inhibition of nucleoside transport by protein kinase inhibitors.

Authors:  Min Huang; Yanhong Wang; Susan B Cogut; Beverly S Mitchell; Lee M Graves
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

Review 7.  Nucleoside transporters in chronic lymphocytic leukaemia.

Authors:  M Pastor-Anglada; M Molina-Arcas; F J Casado; B Bellosillo; D Colomer; J Gil
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

8.  Differential gene regulation by specific gain-of-function JNK1 proteins expressed in Swiss 3T3 fibroblasts.

Authors:  Sun-Young Han; Soo-Hyun Kim; Lynn E Heasley
Journal:  J Biol Chem       Date:  2002-09-26       Impact factor: 5.157

Review 9.  Activation mechanism and physiological roles of stress-activated protein kinase/c-Jun NH2-terminal kinase in mammalian cells.

Authors:  H Nishina; K Nakagawa; N Azuma; T Katada
Journal:  J Biol Regul Homeost Agents       Date:  2003 Oct-Dec       Impact factor: 1.711

10.  Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells.

Authors:  Valerie Levresse; Lindsay Marek; Deborah Blumberg; Lynn E Heasley
Journal:  Mol Pharmacol       Date:  2002-09       Impact factor: 4.436

View more
  7 in total

1.  ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.

Authors:  Mingyang Liu; Yuqing Zhang; Jingxuan Yang; Xiaobo Cui; Zhijun Zhou; Hanxiang Zhan; Kai Ding; Xiang Tian; Zhibo Yang; Kar-Ming A Fung; Barish H Edil; Russell G Postier; Michael S Bronze; Martin E Fernandez-Zapico; Marc P Stemmler; Thomas Brabletz; Yi-Ping Li; Courtney W Houchen; Min Li
Journal:  Gastroenterology       Date:  2019-11-09       Impact factor: 22.682

2.  Decreased extracellular adenosine levels lead to loss of hypoxia-induced neuroprotection after repeated episodes of exposure to hypoxia.

Authors:  Mei Cui; Xue Bai; Tianfu Li; Fangzhe Chen; Qiang Dong; Yanxin Zhao; Xueyuan Liu
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

3.  Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis.

Authors:  Patricia Macanas-Pirard; Andrea Leisewitz; Richard Broekhuizen; Kelly Cautivo; Francisco M Barriga; Francisco Leisewitz; Victoria Gidi; Erick Riquelme; Viviana P Montecinos; Pilar Swett; Pelayo Besa; Pablo Ramirez; Mauricio Ocqueteau; Alexis M Kalergis; Matthew Holt; Michael Rettig; John F DiPersio; Bruno Nervi
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

4.  Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.

Authors:  Patricia Macanas-Pirard; Richard Broekhuizen; Alfonso González; Claudia Oyanadel; Daniel Ernst; Patricia García; Viviana P Montecinos; Felipe Court; Mauricio Ocqueteau; Pablo Ramirez; Bruno Nervi
Journal:  Oncotarget       Date:  2017-04-04

5.  Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma.

Authors:  Qiqing Sun; Wenyan Xu; Shunrong Ji; Yi Qin; Wensheng Liu; Qiangsheng Hu; Zheng Zhang; Mengqi Liu; Xianjun Yu; Xiaowu Xu
Journal:  Cancer Cell Int       Date:  2019-03-04       Impact factor: 5.722

Review 6.  Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications.

Authors:  Jiajia Li; Liyao Peng; Qun Chen; Ziping Ye; Tiantian Zhao; Sicong Hou; Jianguo Gu; Qinglei Hang
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

7.  The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.

Authors:  Lu Chen; Zeyang Wang; Qingwen Xu; Yuxi Liu; Le Chen; Suhang Guo; Hua Wang; Kui Zeng; Junqing Liu; Su Zeng; Lushan Yu
Journal:  Theranostics       Date:  2020-02-18       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.